Boston Scientific Corporation (BIT:1BSX)
Italy · Delayed Price · Currency is EUR | Market Cap | 59.47B -56.2% |
| Revenue (ttm) | 17.88B +17.4% |
| Net Income | 3.09B +75.4% |
| EPS | 2.07 +74.4% |
| Shares Out | n/a |
| PE Ratio | 19.23 |
| Forward PE | 13.28 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 39.22 |
| Previous Close | 38.08 |
| Day's Range | 39.22 - 40.67 |
| 52-Week Range | 37.00 - 92.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatogra... [Read more]
Financial Performance
In 2025, Boston Scientific's revenue was $20.07 billion, an increase of 19.87% compared to the previous year's $16.75 billion. Earnings were $2.90 billion, an increase of 56.40%.
Financial numbers in USD Financial StatementsNews
Boston Scientific unveils new restructuring plan, expects job cuts
Boston Scientific's board has approved a new company-wide restructuring plan aimed at cutting costs and to better position the company for future growth, the medical device maker said in a regulator...
Boston Scientific price target lowered to $85 from $90 at Oppenheimer
Oppenheimer lowered the firm’s price target on Boston Scientific (BSX) to $85 from $90 and keeps an Outperform rating on the shares ahead of quarterly results. The firm is lowering…
Boston Scientific recommending some percutaneous catheters be removed, FDA says
CDRH is issuing and “early alert” to notify the public of a potentially high-risk device issue, the FDA announced. On July 9, Boston Scientific (BSX) sent all affected customers a…
Boston Scientific price target lowered to $62 from $64 at Truist
Truist lowered the firm’s price target on Boston Scientific (BSX) to $62 from $64 and keeps a Buy rating on the shares as part of a broader research note previewing…
Boston Scientific price target lowered to $70 from $90 at Mizuho
Mizuho analyst Anthony Petrone lowered the firm’s price target on Boston Scientific (BSX) to $70 from $90 and keeps an Outperform rating on the shares. The firm adjusted targets in…
Boston Scientific price target lowered to $85 from $100 at RBC Capital
RBC Capital analyst Shagun Singh lowered the firm’s price target on Boston Scientific (BSX) to $85 from $100 and keeps an Outperform rating on the shares as part of a…
Boston Scientific price target lowered to $57 from $77 at Needham
Needham analyst Mike Matson lowered the firm’s price target on Boston Scientific (BSX) to $57 from $77 and keeps a Buy rating on the shares. The management has indicated that…
Boston Scientific put volume heavy and directionally bearish
Bearish flow noted in Boston Scientific (BSX) with 6,918 puts trading, or 1.8x expected. Most active are Jul-26 43 puts and Jul-26 42.5 puts, with total volume in those strikes…
Boston Scientific price target lowered to $65 from $78 at Evercore ISI
Evercore ISI lowered the firm’s price target on Boston Scientific (BSX) to $65 from $78 and keeps an Outperform rating on the shares. The firm’s Q2 preview for MedTech, Life…
Boston Scientific price target lowered to $65 from $75 at Stifel
Stifel lowered the firm’s price target on Boston Scientific (BSX) to $65 from $75 and keeps a Buy rating on the shares after the firm hosted five deep left atrial…
Boston Scientific price target lowered to $67 from $100 at Jefferies
Jefferies lowered the firm’s price target on Boston Scientific (BSX) to $67 from $100 and keeps a Buy rating on the shares. The firm is lowering its Watchman growth estimates…
Boston Scientific management to meet with BTIG
Meeting to be held in New York on June 23 hosted by BTIG.
Boston Scientific price target lowered to $65 from $90 at Piper Sandler
Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Boston Scientific (BSX) to $65 from $90 and keeps an Overweight rating on the shares. The firm notes the…
Boston Scientific price target lowered to $61 from $68 at BofA
BofA lowered the firm’s price target on Boston Scientific (BSX) to $61 from $68 and keeps a Buy rating on the shares. Noting that the firm’s services team continues to…
Belo Sun Announces Management Transition
TORONTO, June 08, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (TSX: BSX) (OTCQX: BSXGF) (the “Company” or “Belo Sun”) today announced a change to its in-country executive leadership team as the Vol...
Boston Scientific price target lowered to $64 from $85 at Truist
Truist lowered the firm’s price target on Boston Scientific (BSX) to $64 from $85 and keeps a Buy rating on the shares. The firm notes the recent management commentary regarding…
Boston Scientific price target lowered to $65 from $80 at BTIG
BTIG analyst Marie Thibault lowered the firm’s price target on Boston Scientific (BSX) to $65 from $80 and keeps a Buy rating on the shares after updating the firm’s forecast…
Boston Scientific put volume heavy and directionally bearish
Bearish flow noted in Boston Scientific (BSX) with 8,246 puts trading, or 2x expected. Most active are Jun-26 47.5 puts and 6/5 weekly 47.5 puts, with total volume in those…
Boston Scientific price target lowered to $70 from $71 at Canaccord
Canaccord lowered the firm’s price target on Boston Scientific (BSX) to $70 from $71 and keeps a Buy rating on the shares. The firm updated its model to reflect slowdowns…
Belo Sun Announces Corporate Update
TORONTO, June 01, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (TSX: BSX) (OTC: BSXGF) (the “Company” or “Belo Sun”) provides the following updates regarding a recent petition filed by the Brazilian...
Boston Scientific slides after flagging slowdown in Watchmen heart device usage
Boston Scientific shares fell about 12% on Wednesday to their lowest in more than two years, after the medical device maker flagged declining usage of its heart disease device.
Boston Scientific Transcript: Bernstein 42nd Annual Strategic Decisions Conference
Management reaffirmed confidence in achieving margin and EPS growth despite lowering 2024 guidance due to challenges in WATCHMAN, EP, and urology. Key growth drivers include new product launches, the Penumbra acquisition, and innovation in TAVR and mapping. Robust pipeline and disciplined capital allocation support a positive long-term outlook.
Belo Sun Announces 2026 Shareholder Meeting Voting Results and Corporate Update
TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX:BSX OTCQX:BSXGF) today is pleased to announce that each of the six individuals nominated for election...
Belo Sun Provides Update on Ongoing Proceedings Before TRF-1
TORONTO, May 21, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX: BSX, OTCQX: BSXGF) is pleased to provide an update regarding hearings held yesterday before the 6th ...